Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Wuhan Landing Medical High Technology

Request full access

Wuhan Landing Medical High Technology is a scientific and technological company

Wuhan, ChinaFounded 2000Health Tech & Medtech

About Wuhan Landing Medical High Technology

Wuhan Landing Medical High-tech Co., Ltd. operates at the intersection of artificial intelligence and pathology to advance early cancer detection. Founded in 2000 by Dr. Xiaorong Sun, the company focuses on creating accessible and affordable diagnostic solutions. Dr. Sun's journey began in 1996 during a research fellowship in Canada where she first encountered digital pathology. Inspired to address the scarcity of pathologists and uneven distribution of healthcare resources in China, she returned in 2001 to launch the company, aiming to make cancer screening widely available and data-driven. After a significant early setback involving a failed partnership, Dr. Sun rebuilt the company, concentrating on developing proprietary AI and medical hardware.

The firm's core business revolves around an AI-powered platform for remote digital pathology analysis, with a primary application in cervical cancer screening. This system utilizes automation, cloud computing, and AI to digitize and analyze cell samples, flagging suspicious cells for review by cytopathologists. This significantly enhances efficiency, allowing one of the company's robots to screen at least 35,000 samples a day compared to the 100 a doctor can screen manually. The business model targets governments, hospitals, and laboratories, providing them with the technology to conduct large-scale screening programs. Revenue is generated through the sale of these AI-powered systems and services, which include slide preparation machines, liquid-based cytology consumables, and digital slide scanners. The company has successfully completed over 10 million AI-assisted cervical cancer screenings.

A key milestone was achieved in 2017 when the company began integrating its technologies into Pap smear testing across China. This led to its selection by the Hubei Provincial Health Commission in 2022 for a massive screening initiative covering over 12 million women. The company has secured approximately $50.1 million in funding over three rounds, with its latest Series D round in November 2021. Investors include Bank of China Group Investment and Alibaba Health Information Technology. Landing Med's technology has gained approvals for marketing in the US, EU, and China and is being implemented in countries like Pakistan, Malaysia, and Indonesia as part of the "Belt and Road Initiative".

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
87.9/100
Industry
Health
Sub-industry
Medical Devices
Sector
Oncology, Health Diagnostics, Spinout, AI for medical imaging, DT and LS, science-based
Technology
Deep Tech
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES D✓Equity / VC Nov 2021 $44M $176M Ether Capital · AliHealth —
SERIES C✓Equity / VC Oct 2018 — — China Merchants Capital · Bank of China Hong Kong —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Wuhan Landing Medical High Technology website traffic

Latest recorded traffic for Wuhan Landing Medical High Technology is 620 monthly website visits, down 21.5% over the last three months. Wuhan Landing Medical High Technology's team grew 40% over the past year.

Latest monthly visits620 3-month web change-21.5% 1-year team growth+40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Wuhan Landing Medical High Technology in the Wuhan ecosystem

Live from Dealroom

The Wuhan Landing Medical High Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Sangel Capital
  • Dalton Venture

Series B and later4 investors entered at this stage

  • China Merchants Capital
  • Bank of China Hong Kong
  • AliHealth
  • Ether Capital

Other known investors1 additional known investor

  • BC Cancer Agency
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Wuhan Landing Medical High Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Wuhan Landing Medical High Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.